drugset / Trial / NCT06516445
SCRT Followed by Camrelizumab Combined With Fluzoparib and Chemotherapy as Neoadjuvant Therapy for LARC
NaSingle-groupOpen-labelTreatment
Summary
To explore the safety and efficacy of neoadjuvant therapy for locally advanced rectal cancer with short course radiotherapy followed by camrelizumab combined with fluzoparib and chemotherapy
Timeline
- Start
- 2023-06-28
- Primary completion
- 2025-06-28
- Completion
- 2026-06-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Capecitabine | Small molecule | 1000 mg/m2 | Oral |
| Subject | Fluzoparib | Small molecule | 100 mg | — |
| Subject | Oxaliplatin | Small molecule | 130 mg/m2 | Intravenous |